FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1

/by

Authors: Delia Soriano, Alicia Brusco, Laura Caltana Published in Behavioural Brain Research November 2020 Abstract Cannabinoid receptor type 1 (CB1R) is the most abundant cannabinoid receptor in central nervous system. Clinical studies and animal models have shown that the attenuation of endocannabinoid system signaling correlates with the development of psychiatric disorders such as anxiety, depression…

Read more

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

/by

Authors: Cathy Davies, Robin Wilson, Elizabeth Appiah-Kusi, Grace Blest-Hopley, Michael Brammer, Jesus Perez, Robin M Murray, Paul Allen, Matthijs G Bossong, Philip McGuire, Sagnik Bhattacharyya Published in Translational Psychiatry September 2020 Abstract Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with altered neural responses to…

Read more

Cannabis and Psychosis: a Critical Overview of the Relationship

/by

Authors: Charles Ksir, Carl L Hart Published in Current Psychiatry Reports February 2016 Abstract Interest in the relationship between cannabis use and psychosis has increased dramatically in recent years, in part because of concerns related to the growing availability of cannabis and potential risks to health and human functioning. There now exists a plethora of scientific…

Read more

Effects on Cannabidiol on Emotion in Psychosis Risk: An FMRI Investigation

/by

Authors: Cathay Davies, Robin Wilson, Elizabeth Appiah-Kusi, Michael Brammer, Jesus Perez, Robin Murray, Paul Allen, Matthijas Bossong, Philip McGuire and Sagnik Bhattacharyya Published in Schizophrenia Bulletin May 2020   Abstract Background There is currently a lack of effective pharmacological treatment for people at Clinical High Risk of Psychosis (CHR), who present with emotional dysregulation and…

Read more

Cannabidiol for psychosis: A review of 4 studies

/by

Authors: Sy Atezaz Saeed, MD, MS, and Kathryn E. Clary, BA Published in Current Psychiatry June 2020   Introduction There has been increasing interest in the medicinal use of cannabidiol (CBD) for a wide variety of health conditions. CBD is one of more than 80 chemicals identified in the Cannabis sativa plant, otherwise known as…

Read more

Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.

/by

Authors: Sanne J. van der Steur, Albert Batalla, Matthijs G. Bossong Published in Brain Sciences 12 February 2020   Abstract Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use or the genetic profile of cannabis users, appear to moderate this association. The present systematic review…

Read more

Possible therapeutic applications of cannabis in the neuropsychopharmacology field.

/by

Authors: Javier Fernández-Ruiz, Ismael Galve-Roperh, Onintza Sagredo, Manuel Guzmán
European Neuropsychopharmacology, 10 February 2020
—
Cannabis use induces a plethora of actions on the CNS via its active chemical ingredients, the so-called phytocannabinoids. These compounds have been frequently associated with the intoxicating properties of cannabis preparations. However, not all phytocannabinoids are psychot…

Read more

Cannabis Use and Hypomania in Young People: A Prospective Analysis .

/by

Authors: Steven Marwaha, Catherine Winsper, Paul Bebbington, Daniel Smith
Schizophrenia Bulletin, November 2018
—
Background: Cannabis use in young people is common and associated with psychiatric disorders. However, the prospective link between cannabis use and bipolar disorder symptoms has rarely been investigated. The study hypothesis was that adolescent cannabis use is associated with…

Read more

Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis.

/by

Authors: Marie Stefanie Kejser Starzer, Merete Nordentoft, Carsten Hjorthøj
American Journal of Psychiatry, April 2018
—
OBJECTIVE: The authors investigated the rates of conversion to schizophrenia and bipolar disorder after a substance-induced psychosis, as well as risk factors for conversion. METHOD: All patient information was extracted from the Danish Civil Registration System and the Psychi…

Read more

Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis.

/by

Authors: Antti Mustonen, Solja Niemelä, Tanja Nordström, Graham K. Murray, Pirjo Mäki, et al
The British Journal of Psychiatry, April 2018
—
BACKGROUND: The association between cannabis use and the risk of psychosis has been studied extensively but the temporal order still remains controversial. Aims To examine the association between cannabis use in adolescence and the risk of psychosis after adjustment for prodro…

Read more

The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

/by

Authors: Britta Hahn
Schizophrenia Bulletin, 13 January 2018
—
A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been un…

Read more

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

/by

Authors: Marta Di Forti, Arianna Marconi, Elena Carra, Sara Fraietta, Antonella Trotta, Matteo Bonomo, et al
The Lancet Psychiatry, March 2015
—
BACKGROUND: The risk of individuals having adverse effects from drug use (eg, alcohol) generally depends on the frequency of use and potency of the drug used. We aimed to investigate how frequent use of skunk-like (high-potency) cannabis in south London affected the associatio…

Read more